Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc. Common Shares (NY:CYBN)

7.416 +0.166 (+2.29%)
Streaming Delayed Price Updated: 2:20 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Australian Approval to Begin EMBRACE Phase 3 Study of CYB003
Via Investor Brand Network
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Annual Meeting Voting Results
Via Investor Brand Network
Cybin Announces Results of Annual Meeting of Shareholders
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q1 2025 Results, Advances Phase 3 Depression Program and Nears Completion of Phase 2 Anxiety Study
Via Investor Brand Network
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives EU Approval to Launch EMBRACE Phase 3 MDD Study
Via Investor Brand Network
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Present at Canaccord Genuity Growth Conference
Via Investor Brand Network
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Receives MHRA Approval to Launch Second Phase 3 Trial for CYB003 in Depression
Via Investor Brand Network
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
3 High-Risk, High-Reward Stocks With Explosive Upside
Rezolve, Aurora, and Cybin are 2025's top growth stocks in AI, driverless trucks, and psychedelics, with huge upside potential and key catalysts unfolding. 
Via MarketBeat
Topics Artificial Intelligence
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures $50 Million in Convertible Debenture Financing from High Trail
Via Investor Brand Network
Topics Intellectual Property
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
– Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs,... 
Via FinancialNewsMedia
Topics Intellectual Property
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
Via Investor Brand Network
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak on Pivotal Trials Panel at Psychedelic Science 2025
Via Investor Brand Network
Cybin to Participate in the 2025 Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming
Federal support for psychedelics is rising fast. One biotech CEO explains what it means for clinical trials, access, and real-world therapy. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
Via Investor Brand Network
Topics Intellectual Property
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.